Nyrada Company Description

Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases.

Its develops oral Proprotein Convertase Subtilisin/Kexin Type 9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; and neuroprotectant drug to reduce long-term disability in patients with traumatic brain injury and ischaemic stroke.

Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.

Nyrada Inc.

Country	United States
Founded	2017
Industry	Biotechnology
Sector	Healthcare
CEO	James Bonnar

Contact Details

Address: Sydney Place Sydney, Delaware 2000 Australia
Phone	61 2 9498 3390
Website	nyrada.com

Stock Details

Ticker Symbol	NYR
Exchange	Australian Securities Exchange
Fiscal Year	July - June
Reporting Currency	AUD
ISIN Number	AU0000070195
SIC Code	2834

Key Executives

Name	Position
James Bonnar	Chief Executive Officer
Cameron Peter Jones C.A.	Chief Financial Officer
Benjamin Evison Ph.D.	Chief Scientific Officer
Dimitri Burshtein	Investor Relations Manager
Mark Waring B.Sc., P.M.P.	Senior Vice President of US Operations
David James Franks BEc, C.A., F Fin, J.P.	Company Secretary